[Gram-positive cocci (include MRSA)].
Tsuji
A
A
Department of Microbiology, Toho University School of Medicine.
D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents; D003982:Dibekacin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D016106:Methicillin Resistance; D015363:Quinolones / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D017334:Teicoplanin / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D015363:Quinolones; D003982:Dibekacin; D017334:Teicoplanin; D014640:Vancomycin; C031986:arbekacin